Ovarian Cancer | Specialty

Dr. Matulonis on the Use of Immunotherapy in Recurrent Ovarian Cancer

January 11th 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the use of immunotherapy in patients with recurrent ovarian cancer.

Dr. Rana on Genetic Testing Guidelines for Patients With Ovarian Cancer

January 9th 2019

Huma Q. Rana, MD, clinical director, Cancer Genetics and Prevention, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses genetic testing guidelines for patients with ovarian cancer.

Dr. Liu on the Use of Bevacizumab in Newly Diagnosed Advanced Ovarian Cancer

January 8th 2019

Joyce F. Liu, MD, MPH, assistant professor of medicine and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses the use of bevacizumab (Avastin) in the treatment of patients with newly diagnosed advanced ovarian cancer.

Dr. Markman Discusses Treating Ovarian Cancer as Chronic Disease

January 4th 2019

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the treatment of ovarian cancer as a chronic disease.

Added Factors Put the Overall Survival Endpoint to the Test

January 3rd 2019

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.

Integrating PARP Inhibitors Into the Treatment of Women

December 30th 2018

After years in development, several PARP inhibitors have achieved indications in ovarian cancer treatment, while others continue in development and expanding indications.

Avelumab Falls Short in Frontline Ovarian Cancer Trial

December 26th 2018

The phase III JAVELIN Ovarian 100 study exploring frontline avelumab in ovarian cancer has been ended after an independent panel determined the study would not meet its primary endpoint of progression-free survival.

Olaparib Succeeds in Confirmatory Trial for Relapsed BRCA+ Ovarian Cancer

December 20th 2018

The PARP inhibitor olaparib demonstrated a statistically significant and clinically meaningful improvement in objective response rate in patients with BRCA-mutant ovarian cancer who have relapsed on at least 2 prior lines of therapy.

Dr. English on Mirvetuximab Soravtansine in Ovarian Cancer

December 20th 2018

Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses the development of the antibody drug conjugate (ADC) mirvetuximab soravtansine in ovarian cancer.

FDA Approves Olaparib for Frontline Maintenance in Ovarian Cancer

December 20th 2018

The FDA has approved olaparib as a maintenance treatment for patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy.

Potential Risks of Genetic Testing in Ovarian Cancer

December 15th 2018

Peter Levonian, MS, senior genetic counselor, Stanford Medicine, discusses the potential risks of genetic testing in ovarian cancer.

Following Pivotal Trials, Questions Remain With Bevacizumab in Recurrent Ovarian Cancer

December 14th 2018

Valerie Sugiyama, MD, discusses the treatment of patients with recurrent ovarian cancer.

EU Panel Backs Maintenance Rucaparib for Ovarian Cancer

December 14th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended to expand the approval of single-agent rucaparib as a maintenance therapy in adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

BRCA Focus in Ovarian Cancer Turns to Preventive Testing for Inherited Mutations

December 13th 2018

The frequency of hereditary mutations that convey an increased risk of ovarian cancer suggests that many cases of the disease are preventable.

New Strategies Are Needed as Ovarian Cancer Becomes a Chronic Disease

December 10th 2018

Since the introduction of platinum agents in ovarian cancer, it is reasonable to suggest there have been only limited changes in the basic paradigm of ovarian cancer management over the past several decades.

New Data Further Demonstrate PARP Inhibitor Impact in Ovarian Cancer

November 29th 2018

David O’Malley, MD, discusses the findings from the SOLO-1 and QUADRA studies, as well as the future of PARP inhibition in ovarian cancer.

Upfront Options Continue to Expand in Advanced Ovarian Cancer

November 29th 2018

Trung Nguyen, DO, MBA, discusses the evolving options for the treatment of patients with newly diagnosed advanced ovarian cancer.

Surgery Remains Standard of Care in Advanced Ovarian Cancer

November 28th 2018

Amer Karam, MD, discussed surgical options for patients with advanced-stage ovarian cancer and the emergence of neoadjuvant chemotherapy.

Novel Agents and the Future Treatment of Ovarian Cancer

November 28th 2018

The Role of I-O in Platinum-Resistant Recurrent OC

November 28th 2018